Rallybio (RLYB) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Rallybio will report Q1 2026 results before the market opens on May 12, 2026, with analysts forecasting a loss of ($1.20) per share and revenue of about $0.227 million (earnings call noted for May 7, 2026 at 7:00 AM ET).
• In the prior quarter Rallybio posted EPS of ($1.03), slightly topping estimates, with revenue of $0.22M, but remains deeply unprofitable with a negative net margin (~1,046%) and negative return on equity (~56.9%).
• Shares trade near $14.05 with a market cap of $74.35M and a negative P/E, and the stock carries a consensus "Sell" rating despite some analysts moving to Hold and heavy institutional ownership (~90%).

Rallybio (NASDAQ:RLYB - Get Free Report) is expected to be announcing its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($1.20) per share and revenue of $0.2270 million for the quarter. Investors are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 7, 2026 at 7:00 AM ET.

Rallybio (NASDAQ:RLYB - Get Free Report) last released its quarterly earnings results on Monday, March 16th. The company reported ($1.03) earnings per share for the quarter, topping analysts' consensus estimates of ($1.04) by $0.01. The business had revenue of $0.22 million during the quarter, compared to the consensus estimate of $0.10 million. Rallybio had a negative net margin of 1,046.39% and a negative return on equity of 56.93%.

Rallybio Trading Down 0.5%

Rallybio stock traded down $0.07 during mid-day trading on Tuesday, reaching $14.05. The company's stock had a trading volume of 276,372 shares, compared to its average volume of 241,753. The firm has a market cap of $74.35 million, a price-to-earnings ratio of -5.47 and a beta of -1.10. The business has a 50 day moving average price of $8.64 and a 200-day moving average price of $6.44. Rallybio has a twelve month low of $2.16 and a twelve month high of $15.31.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised shares of Rallybio to a "hold" rating in a report on Saturday, March 28th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Sell".

Hedge Funds Weigh In On Rallybio

A number of hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC lifted its stake in Rallybio by 16.9% in the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company's stock valued at $573,000 after buying an additional 120,892 shares during the last quarter. Citadel Advisors LLC lifted its stake in Rallybio by 576.1% in the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company's stock valued at $219,000 after buying an additional 373,821 shares during the last quarter. Geode Capital Management LLC lifted its stake in Rallybio by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company's stock valued at $170,000 after buying an additional 2,996 shares during the last quarter. Susquehanna International Group LLP lifted its stake in Rallybio by 485.9% in the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company's stock valued at $68,000 after buying an additional 113,031 shares during the last quarter. Finally, XTX Topco Ltd lifted its stake in Rallybio by 64.6% in the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company's stock valued at $67,000 after buying an additional 38,205 shares during the last quarter. Institutional investors and hedge funds own 90.34% of the company's stock.

Rallybio Company Profile

Rallybio Therapeutics, Inc NASDAQ: RLYB is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company's scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio's pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio's lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.